| Document |
Document Title |
|
WO/2024/071250A1 |
This diamondoid compound is a new compound represented by general formula (1) [in the formula, ring A1 represents an aliphatic ring having two or more rings, R1 represents a hydrogen atom, an alkyl group, a cycloalkyl group, or an adaman...
|
|
WO/2024/067708A1 |
Provided are an ammonium oxalate compound represented by formula (I) or a pharmaceutically acceptable salt, an ester, an optical isomer, a tautomer, a stereoisomer, a polymorph, a solvate, a N-oxide, an isotopically labeled compound, a m...
|
|
WO/2024/066454A1 |
Provided are a targeted protein degradation compound TPB-L-E3B, and a synthetic method therefor and use thereof. Such compounds can be used for treating human tumor diseases by means of an eRF3a targeted degradation mechanism, and have s...
|
|
WO/2024/064726A1 |
Provided herein are methods for preparing 2-azabicyclo[2.2.1]heptan-4-amine, a key structural motif found in a number of synthetic compounds that are inhibitors of rho-associated protein kinase, and its primary amine-protected version te...
|
|
WO/2024/064358A1 |
This disclosure features chemical entities (e.g., a compound of Formula (I), (I-a), (I-b), or (I-c), or a pharmaceutically acceptable salt thereof) that induce degradation of Stimulator of Interferon Genes (STING). Said chemical entities...
|
|
WO/2024/058239A1 |
Provided are: a hole transporting material or an electron blocking material for a photoelectric conversion element for an imaging element including a perylene-based condensed ring compound which can function as a hole transporting materi...
|
|
WO/2024/054807A1 |
Provided is a pharmaceutical composition including a metal channel activator and a TDP-43 modulator. Also provided is a method of treating a depressive disorder, including administering the pharmaceutical composition. Also provided is a ...
|
|
WO/2024/051784A1 |
Provided are a nitrogen-containing heterocyclic compound, a pharmaceutical composition thereof, and use thereof. The structure of the nitrogen-containing heterocyclic compound is represented by formula I. The nitrogen-containing heterocy...
|
|
WO/2024/041660A1 |
The present invention provides a sulfonate-based photoacid generator, a method for preparing same, a method for patterning same, a resist composition thereof, and use thereof. The sulfonate-based photoacid generator is represented by gen...
|
|
WO/2024/042539A1 |
The present disclosutre provides a compound of Formula (I), its stereoisomers, intermediates, or pharmaceutically acceptable salt thereof and a method of preparation of the same. In addition, the present disclosure provides a pharmaceuti...
|
|
WO/2024/038128A1 |
The present invention relates to compounds of Formulas I to V and la to Va, their use as activators of long form cyclic nucleotide phosphodiesterase-4 (PDE4) enzymes (isoforms) and to these compounds for use in a method for the treatment...
|
|
WO/2024/038129A1 |
The present invention relates to compounds of Formulas I to V and Ib to Vb, their use as activators of long form cyclic nucleotide phosphodiesterase-4 (PDE4) enzymes (isoforms) and to these compounds for use in a method for the treatment...
|
|
WO/2024/032530A1 |
Provided are an aromatic heterocyclic cyclohexyl aminoalkyl piperidine derivative, a preparation method and a use thereof. Specifically, provided are a compound of formula (I), a stereoisomer thereof, a tautomer thereof or a pharmaceutic...
|
|
WO/2024/026350A1 |
Compounds having opioid characteristics are provided that can be used for various therapeutic methods including the treatment of pain and opioid use disorders, and compounds having opioid antagonist properties that can be used to treat o...
|
|
WO/2024/017856A1 |
The invention relates to novel compounds having the general formula I wherein R1, R2, X1, X2,X3 and W are as described herein, composition including the compounds and methods of using the compounds.
|
|
WO/2024/020598A1 |
Provided herein are methods of treating nalbuphine-treatable disorders in an elderly patient.
|
|
WO/2024/010782A1 |
Disclosed are compounds of Formula (I) or pharmaceutically acceptable salts or solvates thereof, wherein R1, R3, X, Y, Z, and W arc as defined herein. The compounds are, for example, inhibitors of WRN helicase and useful in treating a pr...
|
|
WO/2024/006252A1 |
The present disclosure relates generally to novel recombinant coronavirus-based fusion proteins ("RBDs-IgG Fe protein" and "RBDs protein") and vaccine compositions using the same, in which the fusion proteins comprise tandemly arranged c...
|
|
WO/2023/249490A1 |
The present invention relates to 3-(sulphonyl or sulfonimidoyl)prop-2-en-1-yl]- 2-oxo-1,2-dihydropyridine-3-carboxamide derivatives having the formula: or the pharmaceutical acceptable salt thereof. The present invention further relates ...
|
|
WO/2023/242105A1 |
The present invention relates to the use of compounds of formula (I) as RAS inhibitors and as a medicament, in particular for use in treating proliferative disorders, inflammatory diseases and/or genetic disorders. The present invention ...
|
|
WO/2023/242355A1 |
The present invention relates to a compound of formula (I), which is a phosphate ester of apomorphine, or a pharmaceutically acceptable salt thereof. The apomorphine phosphate ester according to the invention exhibits remarkably advantag...
|
|
WO/2023/238629A1 |
The present disclosure provides an organic compound characterized by being represented by general formula [1]. In general formula [1], Ar1 and Ar2 are each independently selected from among an aryl group and a heterocyclic group. Ar1 and...
|
|
WO/2023/230702A1 |
Screening for novel antibacterial compounds in small molecule libraries has a low success rate. Here, we applied a machine learning (ML)-based virtual screening for antibacterial activity and evaluated its predictive power by experimenta...
|
|
WO/2023/232019A1 |
Provided are a 7-cyano-8-hydroxyquinoline derivative, a preparation method therefor and a medical use thereof. Specifically, disclosed are a compound represented by general formula (I), a preparation method therefor, a pharmaceutical com...
|
|
WO/2023/221123A1 |
Solid forms of an estrogen receptor (ER) inhibitor, compositions thereof and methods of treating an ER-mediated disorder are provided.
|
|
WO/2023/225563A2 |
The present disclosure relates to compounds that may be used to modulate the activity of a σ2R/TMEM97 receptor. The compounds may be further defined by the formula: (IA), (IB), or (IC) wherein the variables are as described herein. The ...
|
|
WO/2023/225586A2 |
Aspects of this invention are related to novel compounds of Formula I and compositions thereof that are inhibitors of glycogen synthase kinase 3 beta (GSK3β). Some aspects of the invention relate to novel compounds and compositions havi...
|
|
WO/2023/208865A1 |
There is disclosed a compound of Formula (II), a method of manufacturing thereof as well as uses thereof.
|
|
WO/2023/208867A1 |
There is disclosed a compound of Formula (I), a method of manufacturing thereof as well as uses thereof.
|
|
WO/2023/208869A1 |
There is disclosed a compound of Formula (III), a method for manufacturing thereof as well as uses thereof.
|
|
WO/2023/208151A1 |
The present disclosure provides a compound which has an inhibitory effect on USP, a pharmaceutically acceptable salt, a stereoisomer, a solvate or a prodrug thereof, as shown in formula (I), the definition of each group in the formula be...
|
|
WO/2023/199091A1 |
The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. [Solving Means] A compound represented by the formula (I) is useful as an agent for the prophylaxis or treatment of narcolepsy.
|
|
WO/2023/196454A1 |
The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, esters, or prodrugs thereof: Formula (I) which inhibit Human Respiratory Syncytial Virus (HRSV) or Human Metapneumovirus (HMPV) inhibitors. ...
|
|
WO/2023/172649A9 |
The present invention relates to a drug approved for the treatment of hypomobility in patients with Parkinson's disease. The invention further relates to apomorphine hydrochloride trimethanolate (III), its polymorphs, pharmaceutical uses...
|
|
WO/2023/187677A1 |
Disclosed are compounds of Formula 1, and pharmaceutically acceptable salts thereof, wherein L6, n, R2, R3, R4, R5, R7, R8, R9, R10, R11, R12, R13, R14, R15 and X1 are defined in the specification. This disclosure also relates to materia...
|
|
WO/2023/187099A1 |
The invention relates to morphinan-derivatives, processes for their preparation, medicaments containing them and the use of these morphinan-derivatives for the preparation of medicaments.
|
|
WO/2023/160302A9 |
A C19 diterpene alkaloid, a preparation method therefore and an application thereof, which relate to the technical field of medicines. The structure of the C19 diterpene alkaloid is shown in formula (I). Pharmacodynamic experiments show ...
|
|
WO/2023/178809A1 |
A synthesis method for nuciferine or a derivative thereof, a nuciferine derivative and an application thereof. A compound having a structure shown in formula IV and R-X undergo a Schotten-Baumann reaction, and then nuciferine having a st...
|
|
WO/2023/179205A1 |
Provided are a diimide derivative, a preparation method therefor and the use thereof. The diimide derivative has a good anti-tumor activity, and the anti-proliferative activity against various cancer cells is significantly better than th...
|
|
WO/2023/166531A1 |
The present disclosure provides a compound of Formula I which are naphthalene monoimide compounds, and process of preparing thereof. The compounds of the present disclosure provide reversal of cognitive decline or improvement of cognitiv...
|
|
WO/2023/164889A1 |
Disclosed are a method for preparing codeine and a derivative and intermediate thereof. Simple, cheap and easily-available commercially available compounds are used as starting materials in the present invention, various intermediates th...
|
|
WO/2023/156565A1 |
Disclosed herein are certain therapeutic substituted heterocyclic bridged ring compounds, including substituted morpholine, thiomorpholine, and piperidine compounds and their homologues, having various advantages over current compounds u...
|
|
WO/2023/158722A2 |
The present disclosure encompasses a process for chiral resolution of racemic amines, particularly ethyl 2-(4-((tert-butoxycarbonyl)amino)phenyl)piperidine-3-carboxy
late, into its desired isomer, ethyl (2R,3S)-2-(4-((tert-butoxycarbonyl...
|
|
WO/2023/154499A1 |
Provided are compounds of the Formula (I) or pharmaceutically acceptable salts thereof, which are useful for the inhibition of EBP and in the treatment of a variety of EBP mediated conditions or diseases, such as multiple sclerosis.
|
|
WO/2023/152346A1 |
The present invention relates to compounds that are suitable for use in electronic devices, and to electronic devices, more particularly organic electroluminescent devices, containing these compounds.
|
|
WO/2023/142857A1 |
Disclosed in the present invention is a preparation method of Rimegepant. Specifically, the preparation method comprises the following steps: 1) reacting a compound of formula (III) with a compound of formula (IV) in a solvent 1, in the ...
|
|
WO/2023/138657A1 |
A quinoline amine compound, a preparation method therefor, and the use thereof in medicine. Specifically, the present disclosure relates to a quinoline amine compound represented by general formula (I), a preparation method therefor, a p...
|
|
WO/2023/137962A1 |
Disclosed in the present invention is an oxidized isoaporphine alkaloid derivative having a structure as shown in formula I, wherein R1 and R2 are independently selected from H, F, Cl and methoxy, respectively; and n is an integer of 2-6...
|
|
WO/2023/126951A1 |
Disclosed herein are inhibitors of autophagy-related protein-protein interactions and their use for treating an autophagy-related disease or disorder, cancer, a cytokine release syndrome (CRS) or a cytokine storm in a subject.
|
|
WO/2023/112056A1 |
The present invention provides a compound formula (I), Formula (I) wherein, R1, R2, R3, R5, R6, R7, R8, R9, X, Z1 and Z2 are as defined in the detailed description and a process for preparing the compound of formula (I). The present inve...
|
